Cardiopulmonary bypass and the systemic inflammatory response: Effects on drug action

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 16, Issue 1, 2002, Pages 83-98

  Hall, Richard I ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Cardiopulmonary bypass; Pharmacodynamics; Pharmacokinetics; Systemic inflammatory response

Indexed keywords

ALFENTANIL; ANESTHETIC AGENT; BARBITURIC ACID DERIVATIVE; CEFAZOLIN; CIMETIDINE; DIAZEPAM; DIGOXIN; DILTIAZEM; DOBUTAMINE; DOPAMINE; ERYTHROMYCIN; ETOMIDATE; FENTANYL DERIVATIVE; GLYCERYL TRINITRATE; KETAMINE; LIDOCAINE; LORAZEPAM; METHOHEXITAL; METHYLPREDNISOLONE; METOPROLOL; MIDAZOLAM; ONDANSETRON; OPIATE DERIVATIVE; PROPOFOL; PROPRANOLOL; SUFENTANIL; THEOPHYLLINE DERIVATIVE; THIOPENTAL; UNINDEXED DRUG; VASOPRESSIN;

CARDIOPULMONARY BYPASS; DRUG DISPOSITION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; HYPOTHERMIA; PRIORITY JOURNAL; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TEMPERATURE SENSITIVITY;

EID: 0036168662     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/jcan.2002.29690     Document Type: Article

References (238)

1. Anaesthesia for coronary artery surgery - A plea for a goal-directed approach
2. Early tracheal extubation after coronary artery bypass graft surgery reduces costs and improves resource use: A prospective, randomized, controlled trial
3. Morbidity outcome in early versus conventional tracheal extubation after coronary artery bypass grafting: A prospective randomized controlled trial
4. Off-pump versus on-pump coronary artery bypass surgery and postoperative renal dysfunction
5. Serum S-100 protein release and neuropsychologic outcome during coronary revascularization on the beating heart: A prospective randomized study
6. Effect of cardiopulmonary bypass on pulmonary gas exchange: A prospective randomized study
7. Predictors of atrial fibrillation after conventional and beating heart coronary surgery: A prospective, randomized study
8. Beating versus arrested heart revascularization: Evaluation of myocardial function in a prospective randomized study
9. On-pump versus off-pump coronary revascularization: Evaluation of renal function
10. Inflammatory response after coronary revascularization with or without cardiopulmonary bypass
11. Avoiding cardiopulmonary bypass in multivessel CABG reduces cytokine response and myocardial injury
12. Effect of cardiopulmonary bypass on the pharmacokinetics of drugs
13. Cardiopulmonary bypass and the pharmacokinetics of drugs: An update
14. The pharmacokinetic behaviour of opioids administered during cardiac surgery
15. The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass
16. Changes in the pharmacokinetics and pharmacodynamics of drugs administered during cardiopulmonary bypass
17. Pharmacokinetics of analgesics, sedatives and anaesthetic agents during cardiopulmonary bypass
18. Thiopentone levels during cardiopulmonary bypass: Changes in plasma protein binding during continuous infusion
19. The effects of cardiopulmonary bypass on total and unbound plasma concentrations of propofol and midazolam
20. The effect of cardiopulmonary bypass on plasma protein binding of alfentanil
21. An improved lidocaine infusion protocol for cardiac surgical patients
22. Free and total lidocaine levels in cardiac surgical patients
23. The effect of cardiopulmonary bypass on plasma concentrations and protein binding of methohexital and thiopental
24. Binding of fentanyl and alfentanil to the extracorporeal circuit
25. Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen
26. ε-Aminocaproic acid plasma levels during cardiopulmonary bypass
27. Effects of cardiopulmonary bypass on teicoplanin serum disposition
28. Teicoplanin concentrations in serum, pericardium, pericardial fluid and thoracic wall fat in patients undergoing cardio-pulmonary bypass surgery
29. Effects of cardiopulmonary bypass on vancomycin plasma concentration decay
30. Ketamine concentrations during cardiopulmonary bypass
31. Cardiopulmonary bypass-induced changes in plasma concentrations of propofol and in auditory evoked potentials
32. Pharmacokinetics and temperature
33. The influence of hypothermia on the disposition of fentanyl - Human and animal studies
34. Effects of hypothermia on propranolol kinetics
35. Influence of hypothennia on the pharmacokinetics of gentamicin and theophylline in piglets
36. Hypothermia and the pharmacokinetics and pharmacodynamics of pancuronium in the cat
37. Compartmental analysis of lidocaine kinetics during extracorporeal circulation
38. Normothermic cardiopulmonary bypass
39. Systemic effects of normothermic cardiopulmonary bypass
40. Pulsatile and nonpulsatile perfusion: The continuing controversy
41. Thiopentone pharmacokinetics during cardiopulmonary bypass with a nonpulsatile or pulsatile flow
42. Coronary artery bypass grafting without cardiopulmonary bypass
43. Human cytokine responses to cardiac transplantation and coronary artery bypass grafting
44. Cytokine responses to cardiopulmonary bypass: Lessons learned from cardiac transplantation
45. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass
46. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL- 10 produced by monocytes
47. Therapeutic implications of interleukin-10 in surgical disease
48. Hirudin as anticoagulant for cardiopulmonary bypass: Importance of preoperative renal function
49. Atrial fibrillation after beating heart surgery
50. Fentanyl sequestration in lungs during cardiopulmonary bypass
51. First-pass pulmonary retention of sufentanil at three different background blood concentrations of the opioid
52. Effect of ventilation on first-pass pulmonary retention of alfentanil and sufentanil in patients undergoing coronary artery surgery
53. Pulmonary kinetics of fentanyl and alfentanil in surgical patients
54. First pass uptake of fentanyl, meperidine, and morphine in the human lung
55. Association between gastric intramucosal pH and splanchnic endotoxiu, antibody to endotoxin, and tumor necrosis factor-alpha concentrations in patients undergoing cardiopulmonary bypass
56. Predictive value of the stomach wall pH for complications after cardiac operations: Comparison with other monitoring
57. Sodium bicarbonate in the treatment of subtypes of acute lactic acidosis: Physiologic considerations
58. Magnesium metabolism in patients undergoing cardiopulmonary bypass
59. Potassium and openheart surgery
60. The importance of calcium and magnesium ions in serum and cerebrospinal fluid during cardiopulmonary bypass
61. Loss of nitroglycerin to cardiopulmonary bypass apparatus
62. Sequestration of glyceryl trinitrate (nitroglycerin) by cardiopulmonary bypass oxygenators
63. In vitro uptake and elimination of isoflurane by different membrane oxygenators
64. Isoflurane uptake and elimination are delayed by absorption of anesthetic by the Scimed membrane oxygenator
65. Sequestration of fentanyl by the cardiopulmonary bypass (CPBP)
66. Fentanyl uptake by the Scimed Membrane oxygenator
67. Propofol sequestration within the extracorporeal circuit
68. Is sufentanil removed by blood conservation devices?
69. Renal considerations, dialysis, and ultrafiltration during cardiopulmonary bypass
70. Derivation of sieving coefficients to determine the efficacy of the hemoconcentrator in removal of four inflammatory mediators produced during cardiopulmonary bypass
71. Cardiopulmonary bypass in infants and children: How is it different?
72. Recent advances in paediatric cardiopulmonary bypass
73. Efficacy of ultrafiltration in removing inflammatory mediators during pediatric cardiac operations
74. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: Assessment of different filter systems
75. The effects of haemofiltration on cefazolin levels during cardiopulmonary bypass
76. Hepatic drug metabolism in critical illness
77. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil: An update
78. The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: Measurement of alfentanil hepatic extraction coefficient
79. Hepatic blood flow during cardiopulmonary bypass operations: The effect of temperature and pulsatility
80. Splanchnic oxygen transport and lactate metabolism during normothermic cardiopulmonary bypass in humans
81. Gastric intramucosal pH and hepatic venous oximetry after cardiopulmonary bypass in valve replacement patients
82. Regulation of cytochromes P 450 during inflammation and infection
83. Molecular mechanisms of drug metabolism in the critically ill
84. Modulation of drug metabolism in infectious and inflammatory diseases
85. The human hepatic cytochromes P 450 involved in drug metabolism
86. Possible involvement of multiple cytochrome P 450S in fentanyl and sufentanil metabolism as opposed to alfentanil
87. The effect of oxygen on propofol-induced inhibition of microsomal cytochrome P 450 3A4
88. Human cytochrome P450 mono-oxygenase system is suppressed by propofol
89. The physiological and pharmacological roles of cytochrome P 450 isoenzymes
90. Adverse drug interactions in anesthesia
91. "It's the genes, stupid": Molecular bases and clinical consequences of genetic cytochrome P 450 2D6 polymorphism
92. Cytochrome P-4502EI: Its physiological ard pathological role
93. Hepatic drug metabolism and immunostiraulation
94. Pharmacokinetics and pharmacodynamics in critically ill patients
95. What changes drug metabolism in critically ill patients?: II. Serum inhibits the metabolism of midazolam in human microsomes
96. What changes drug metabolism in critically ill patients? Two preliminary studies in isolated human hepatocytes
97. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy
98. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass
99. Effects of hypothermia on blood endogenous endotoxin levels during cardiopulmonary bypass
100. The systemic inflammatory response to cardiopulmonary bypass: Pathophysiological, therapeutic, and pharmacological considerations
101. Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women
102. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism
103. Cytokines down-regulate expression of major cytochrome P- 450 enzymes in adult human hepatocytes in primary culture
104. Role of nitric oxide in the cytokine-mediated regulation of cytochrome P- 450
105. Hepatic and central nervous system cytochrome P450 are down-regulated during lipopolysaccharide-evoked localized inflammation in brain
106. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery
107. Adverse cerebral outcomes after coronary bypass surgery. Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation Investigators
108. Effects of cardiac surgery with cardiopulmonary bypass on lidocaine disposition
109. Plasma propranolol before, during, and after cardiopulmonary bypass
110. Ceftriaxone disposition in open-heart surgery patients
111. Disease-induced changes in the plasma binding of basic drugs
112. Cerebral swelling after normothermic cardiopulmonary bypass
113. Longer duration of cardiopulmonary bypass is associated with greater numbers of cerebral microemboli
114. Does hypothermia or hyperventilation affect enflurane MAC reduction following partial cardiopulmonary bypass in dogs?
115. Does cardiopulmonary bypass alter enflurane requirements for anesthesia?
116. Factors influencing MAC reduction after cardiopulmonary bypass in dogs
117. Cardiopulmonary bypass does not alter canine enflurane requirements
118. Anesthetic requirements decrease after cardiopulmonary bypass
119. Effects of normothermic cardiopulmonary bypass on bispectral index
120. Cerebral physiologic effects of burst suppression doses of propofol during nonpulsatile cardiopulmonary bypass. CNS Subgroup of McSPI
121. Propofol does not ameliorate cerebral venous oxyhemoglobin desaturation during hypothermic cardiopulmonary bypass
122. Neuropsychiatric complications after cardiopulmonary bypass: Cerebral protection by a barbiturate
123. Effect of thiopental on neurologic outcome following corollary artery bypass grafting
124. Pharmacologic electroencephalographic suppression during cardiopulmonary bypass: A comparison of thiopental and isoflurane
125. Pulsatility does not change cerebral oxygenation during cardiopulmonary bypass
126. Pure opioid versus opioid-volatile anesthesia for coronary artery bypass graft surgery A prospective, randomized, double-blind study
127. Blood pressure response and plasma fentanyl concentrations during high- and very high-dose fentanyl anesthesia for coronary artery surgery
128. Hemodynamic changes prior to and after sternotomy in patients anesthetized with high-dose fentanyl
129. Fentanyl and sufentanil anesthesia revisited: How much is enough?
130. Effects of anaesthesia based on high versus low doses of opioids on the cytokine and acute-phase protein responses in patients undergoing cardiac surgery
131. Physiologic stress and cellular ischemia: Relationship to immunosuppression and susceptibility to sepsis
132. Opioid and opiate immunoregulatory processes
133. Opioids in cardiac surgery: Cardiopulmonary bypass and inflammatory response
134. Delta2 opioid receptor subtype on human vascular endothelium uncouples morphine-stimulated nitric oxide release
135. Morphine inhibits NF-kappaB nuclear binding in human neutrophils and monocytes by a nitric oxide-dependent mechanism
136. Immunoregulatory effects of morphine on human lymphocytes
137. Opioid-mediated suppression of interferon-gamma production by cultured peripheral blood mononuclear cells
138. Morphine's immunoregulatory actions are not shared by fentanyl
139. Methionine-enkephalin stimulates interleukin-6 mRNA expression: Human plasma levels in coronary artery bypass grafting
140. Does intrathecal morphine alter clothe stress response following coronary artery bypass grafting surgery?
141. Large-dose intrathecal morphine for coronary artery bypass grafting
142. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity
143. Induction of interleukin-1 production in patients undergoing cardiopulmonary bypass
144. Inflammatory response to cardiopulmonary bypass: Mechanisms involved and possible therapeutic strategies
145. Synthesis of interleukin 6 (interferon -beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP
146. Differential effects of beta-endorphin on cAMP levels in human peripheral blood mononuclear cells
147. cAMP inhibition of interleukin-1-induced interleukin-6 production by human lung fibroblasts
148. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway
149. Acute depression of myocardial beta-adrenergic receptor signaling during cardiopulmonary bypass: Impairment of the adenylyl cyclase moiety
150. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil: I. Model development
151. Decreased fentanyl and alfentanil dose requirements with age: A simultaneous pharmacokinetic and pharmacodynamic evaluation
152. Effect of age on MAC in humans: A metaanalysis
153. Hypothermia eliminates isoflurane requirements at 20 degrees C
154. Effects of hypothermia on halothane MAC and isoflurane MAC in the rat
155. Effects of temperature on the interaction of morphine with opioid receptors
156. The analysis of the mode of action of curare on neuromuscular transmission: The effect of temperature changes
157. The influence of hypothermic cardiopulmonary bypass on neuromuscular transmission in the absence of muscle relaxants
158. Variations in pancuronium requirement, plasma concentration, and urinary excretion induced by cardiopulmonary bypass with hypothermia
159. Unequal effects of cardiopulmonary bypass-induced hypothermia on neuromuscular blockade from constant infusion of alcuronium, d-tubocurarine, pancuronium, and vecuronium
160. Greater neuromuscular blocking potency of atracurium during hypothermic than dining normothermic cardiopulmonary bypass
161. Changes in plasma cholinesterase activity and mivacurium neuromuscular block in response to normothermic cardiopulmonary bypass
162. Effects of temperature on phrenic nerve and diaphragmatic function during cardiac surgery
163. Metocurine kinetics in patients undergoing operations requiting cardiopulmonary bypass
164. Effects of hypothermic cardiopulmonary bypass on the pharmacodynamics and pharmacokinetics of rocuronium
165. Pharmacodynamics of doxacurium during cardiac surgery with hypothermic cardiopulmonary bypass
166. Hypothermic cardiopulmonary bypass and neuromuscular blockade by pancuronium and vecuronium
167. Desflurane pharmacokinetics during cardiopulmonary bypass
168. In vitro anesthetic washin and washout via bubble oxygenators: Influence of anesthetic solubility and rates of carrier gas inflow and pump blood flow
169. Washin and washout of isoflurane administered via bubble oxygenators during hypothermic cardiopulmonary bypass
170. Washin and washout of isoflurane during cardiopulmonary bypass
171. Isoflurane elimination via a bubble oxygenator during extracorporeal circulation
172. Blood/gas solubility coefficient and blood concentration of enflurane during normothermic and hypothermic cardiopulmonary bypass
173. Effect of temperature on the solubility of desflurane, sevoflurane, enflurane and halothane in blood
174. Hematocrit and the solubility of volatile anesthetics in blood
175. A comparison of anaesthetic tensions in arterial blood and oxygenator exhaust gas during cardiopulmonary bypass
176. Isoflurane and hypothermic cardiopulmonary bypass: Vasodilation without metabolic effects
177. Effects of sevoflurane and isoflurane on systemic vascular resistance: Use of cardiopulmonary bypass as a study model
178. Effects of rapid increases of desflurane and sevoflurane to concentrations of 1.5 MAC on systemic vascular resistance and catecholamine response during cardiopulmonary bypass
179. Effects of desflurane and isoflurane on systemic vascular resistance during hypothermic cardiopulmonary bypass
180. The pharmacodynamic interaction of propofol and alfentanil during lower abdominal surgery in women
181. Pharmacokinetic model driven infusion of propofol in children
182. Administration of propofol by target-controlled infusion in patients undergoing coronary artery surgery
183. Pharmacokinetic model-driven infusion of sufentanil and midazolam during cardiac surgery: Assessment of the prospective predictive accuracy and the quality of anesthesia
184. Pharmacokinetics of midazolam in patients recovering from cardiac surgery
185. Linearity of pharmacokinetics and model estimation of sufentanil
186. Fentanyl plasma concentrations maintained by a simple infusion scheme in patients undergoing cardiac surgery
187. Effect of cardiopulmonary bypass on the plasma concentrations of fentanyl and alcuronium
188. Vecuronium pharmacokinetics and pharmacodynamics during hypothermic cardiopulmonary bypass in infants and children
189. Dose requirements of infusions of cisatracurium or rocuronium during hypothermic cardiopulmonary bypass
190. Effect of hypothermia on the hepatic uptake and biliary excretion of vecuronium in the isolated peffused rat liver
191. Corticosteroids during operations using cardiopulmonary bypass
192. No steroids or STITCH for CPB?
193. Glucocorticoid reduction of bronchial epithelial inflammation during cardiopulmonary bypass
194. Glucocorticoids blunt neutrophil CDI Ib surface glycoprotein upregulation during cardiopulmonary bypass in humans
195. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans
196. Pulmonary effects of methylprednisotone in patients undergoing coronary artery bypass grafting and early tracheal extubation
197. Does steroid pretreatment increase endotoxin release during clinical cardiopulmonary bypass?
198. The effects of methylprednisolone on complement, immunoglobulins and pulmonary neutrophil sequestration during cardiopulmonary bypass
199. Influence of methylprednisolone on cytokine balance during cardiac surgery
200. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells
201. Negative inotropic effects of cytokines on the heart mediated by nitric oxide
202. Hemodynamic effects of methylprednisolone in patients undergoing cardiac operation and early extubation
203. Assessment of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure
204. Increasing splanchnic blood flow in the critically ill
205. Jejunal mucosal perfusion is well maintained during mild hypothermic cardiopulmonary bypass in humans
206. The effect of intestinal hypoperfusion on intestinal absorption and permeability during cardiopulmonary bypass
207. Effect of cardiopulmonary bypass perfusion protocols on gut tissue oxygenation and blood flow
208. The effect of cardiopulmonary bypass on gastric and colonic mucosal perfusion: A tonometric assessment
209. The role of the gut in the development of multiple organ dysfunction in cardiothoracic patients
210. A placebo-controlled study of the effects of dopexalnine on gastric mucosal perfusion in infants undergoing hypothermic cardiopulmonary bypass
211. Gut mucosal perfusion in infants undergoing cardiopulmonary bypass: Effect of preoperative captopril
212. Effect of sodium nitroprusside on complement activation induced by cardiopulmonary bypass: A clinical and experimental study
213. The nitrovasodilators: New ideas about old drugs
214. Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells
215. The influence of cardiopulmonary bypass on cytokines and cell-cell communication
216. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: An insight into endotoxin shock
217. Endothelial cell injury in cardiovascular surgery: The pathophysiology of vasomotor dysfunction
218. Cerebral physiology in paediatric cardiopulmonary bypass
219. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery
220. Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashortacting dihydropyridine, during cardiopulmonary bypass
221. Use of atracurium in cardiac surgery involving cardiopulmonary bypass with induced hypothermia
222. Effect of temperature and cardiopulmonary bypass on the pharmacokinetics of remifentanil
223. The effect of cardiopulmonary bypass on cholinesterase activity
224. Pharmacokinetics of epsilon-aminocaproic acid in patients undergoing aortocoronary bypass surgery
225. The absorption, distribution, and excretion of ε-aminocaproic acid following oral or intravenous administration to man
226. Kinetics of epsilon-aminocaproic acid distribution, elimination, and antifibrinolytic effects in normal subjects
227. Gender does not influence epsilon-aminocaproic acid concentrations in adults undergoing cardiopulmonary bypass
228. The association of epsilon-aminocaproic acid with postoperative decrease in creatinine clearance in 1502 coronary bypass patients
229. Plasma tranexamic acid concentrations during cardiopulmonary bypass
230. Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA
231. Aprotinin versus lysine analogues: The debate continues
232. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs
233. Influence of highand low-dose aprotinin on activation of hemostasis in open heart operations
234. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage
235. Plasma aprotinin concentrations during cardiac surgery: Full- versus half-dose regimens
236. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting
237. Aprotinin does not impair renal haemodynamics and function after cardiac surgery
238. Aprotinin in primary valve replacement and reconstruction: A muhicenter, double-blind, placebo-controlled trial